China Innovative Drug ETFs See Net Inflows; GF CSI Innovative Drug ETF Adds RMB 526 Million in a Week

Innovative drug-related ETFs in China recorded net fund inflows over the past week through June 30, with the GF CSI Innovative Drug Industry ETF seeing a net increase of RMB 526 million, according to 36Kr. The GF CSI Hong Kong Innovative Drug ETF and the Guotai SSE STAR Market Innovative Drug ETF each posted net inflows of more than RMB 400 million, while products including the E Fund CSI Innovative Drug Industry ETF and the Huitianfu Guozheng Hong Kong Stock Connect Innovative Drug ETF also saw additional buying.